Fig. 6

Combining IN10018 with crizotinib suppressed the growth of the TNBC xenograft models. The control group was treated with 0.5% natrosol 250 HX by intragastric administration once a day. IN10018 or crizotinib group were given intragastric administration of 25 mg/kg once a day. A Representative images of MDA-MB-231 tumors. B Growth curves of MDA-MB-231 tumors. C Tumor weights of MDA-MB-231 tumors. D Mouse weight of MDA-MB-231 tumors. E Immunohistochemical staining and quantitative analysis of the subcutaneous tumor tissues. Data are represented as mean ± SEM. Significant levels: ns = not significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 0.001